Journal: Briefings in Bioinformatics

Article Title: New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges

doi: 10.1093/bib/bbae028

Figure Lengend Snippet: Comparison of approaches used in the identification of the site of origin in CUP

Article Snippet: , 13 , 2010 , Rosetta Genomics Ltd et al. [ ] , 356 , Self-collected cases , FFPE , RNA , 25 , 90.00% , Yes , 204 , No , 85.00% , Yes , No , NA , MicroRNA array + qRT-PCR.

Techniques: Comparison, Sequencing, Mutagenesis, Expressing, Genome Wide, Gene Expression, Real-time Polymerase Chain Reaction, Microarray, Plasmid Preparation, Reverse Transcription, RNA Sequencing, Selection, DNA Methylation Assay, Biomarker Discovery

Journal: PLoS ONE

Article Title: MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma

doi: 10.1371/journal.pone.0139305

Figure Lengend Snippet: Clinical features, demographics and laboratory values of the patient cohorts. The aforementioned parameters are presented in Table 2 (Serum). Patients with primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CC) were compared regarding demographics, laboratory and microRNA (miRNA) values. Data were expressed as number or median with interquartile range (IQR). ECC: extrahepatic cholangiocarcinoma; ICC: intrahepatic cholangiocarcinoma; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; CRP: C-reactive protein; WBC: white blood cells; CA 19–9: carbohydrate antigen 19–9.

Article Snippet: Global profiling of miRNA levels was performed by using a miRNome microRNA Profiler QuantiMir Human PCR Array (#RA660A-1, version 15; BioCat, Heidelberg, Germany) according to manufacturer’s instructions.

Techniques: AST Assay

Journal: PLoS ONE

Article Title: MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma

doi: 10.1371/journal.pone.0139305

Figure Lengend Snippet: Clinical features, demographics and laboratory values of the patient cohorts. The aforementioned parameters are presented in Table 3 (Bile). Patients with primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CC) were compared regarding demographics, laboratory and microRNA (miRNA) values. Data were expressed as number or median with interquartile range (IQR). ECC: extrahepatic cholangiocarcinoma; ICC: intrahepatic cholangiocarcinoma; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; CRP: C-reactive protein; WBC: white blood cells; CA 19–9: carbohydrate antigen 19–9.

Article Snippet: Global profiling of miRNA levels was performed by using a miRNome microRNA Profiler QuantiMir Human PCR Array (#RA660A-1, version 15; BioCat, Heidelberg, Germany) according to manufacturer’s instructions.

Techniques: AST Assay

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Splenic RNA and microRNA mimics promote complement factor B production and the alternative pathway activation via innate immune signaling

doi: 10.4049/jimmunol.1502106

Figure Lengend Snippet: A. Heat map of miRNA array. Mice were subjected to Sham or CLP procedure. At 24 hours, plasma was collected and miRNAs were analyzed using Firefly microRNA array provided by Firefly BioWorks. Sham (n=4) and CLP (n=5) mice. The fluorescence intensity of 56 miRNAs was expressed from low (green) to high (red). B. Fold change in the plasma miRNAs in the CLP compared to that of Sham mice (CLP/Sham) as measured by miRNA array. C. Mean fluorescent intensity of plasma miRNAs as measured by miRNA array in Sham and CLP mice. Six miRNAs (miR-145, miR-122, miR-192, miR-146a, miR-34a, miR-210) were significantly increased for more than 2-fold in the septic mice compared to the sham control. .* P < 0.05, ** P < 0.01, **** P < 0.001. n=4 in sham group, n=5 in CLP group. D. qRT-PCR validation of miRNAs. The 6 target miRNAs were tested using qRT-PCR in a separate set of plasma. * P < 0.05, ** P < 0.01. n=8 in sham group, n=10 in CLP group.

Article Snippet: At 24 hours, plasma was collected and miRNAs were analyzed using Firefly microRNA array provided by Firefly BioWorks.

Techniques: Clinical Proteomics, Fluorescence, Control, Quantitative RT-PCR, Biomarker Discovery